Zum Inhalt springen
Sponsorship
Die MVF-Knowledge-HubsFrisch aus der Forschung. Täglich aktualisiert!

Suchen Sie in Hunderten nationaler und internationaler Datenbanken nach dem neuesten Studienwissen der angegebenen Themengebiete und/oder lassen Sie sich werktäglich per Newsletter informieren. Die Newsfeeds werden auf deutsch übersetzt and nach Übertragbarkeit auf das deutsche Gesundheits-/Versorgungssystem ausgewählt:

Zu den Knowledge-Hubs

Transfer to standard care is still controversial

How much diversity of actors and how much competition is in the draft bill for the Statutory Health Insurance Care Strengthening Act - this was one of the central questions at the discussion forum of the Federal Managed Care Association (BMC) on November 10th. in Berlin. Under the title “How much reform power is there in the VSG: New options through innovation funds and 'special care'?” representatives from health insurance companies, service providers and industry discussed with BMG department head Dr. Ulrich Orlowski on the innovation fund and the new selective contract regulations. At the same time, the BMC presented a statement calling, among other things, for the expansion of those eligible to apply for innovation funds and “special care”.

Read more
First publication date: 16.10.2014

Additional Information

Plain Text

>> The recently presented draft bill for the Statutory Health Insurance Care Strengthening Act touches on a variety of topics. At the beginning of November, the BMC therefore organized a discussion forum for all interested parties, with BMG department head Dr. Ulrich Orlowski discussed intensively the design and opportunities of the innovation fund, the newly designed legal framework for selective contracts and the changes to outpatient and inpatient care structures.
The BMC has been calling for the establishment of an innovation fund for a long time: “The fund is a real opportunity to provide new impetus for the reform of supply structures,” said Prof. Dr. Volker Amelung, Chairman of the BMC. “However, so that funding applications are decided on the basis of factual rather than political criteria, it would make sense for the Innovation Committee to be more independent from its sponsor, the G-BA.” Dr. Rolf-Ulrich Schlenker, deputy chairman of the board of BARMER GEK and board member of the BMC, was concerned about the weighting of votes and composition of the innovation committee: “In order to underline the independence, a broader structure of the innovation committee would be recommended, for example by including scientists, patient representatives or even the Ministry of Science.” From the perspective...

... subscribers can find the detailed interview in archive

Do you want to leave us already?

Subscribe to our newsletter quickly. Then you can be sure that you won't miss anything.